SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Howe Sound Research | PRODUCT CODE: 2171565

Cover Image

PUBLISHER: Howe Sound Research | PRODUCT CODE: 2171565

Metagenomic Sequencing Markets: Market Forecast, Competitive Landscape, Technology and Policy Outlook, 2027-2031

PUBLISHED:
PAGES: 290 Pages; 23 Chapters; 60 Tables; 49 Figures
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 6995
PDF (Five User License)
USD 9995
PDF (Enterprise License)
USD 13995

Add to Cart

Report Overview:

Metagenomic sequencing is moving from the research bench into routine clinical and public health use. This report estimates the global metagenomic sequencing market at $2,460 million in 2026, growing 18.7% a year to $5,800 million in 2031 and adding $3,340 million of new annual spending. Clinical infectious disease adds the most new revenue, $1,166 million, and rises from 24.5% to 30.5% of the market, while public health and wastewater surveillance grows fastest at 31.1% a year. Shotgun and long-read sequencing take share from 16S methods, and clinical laboratories and hospitals overtake academic institutions as the largest customers by 2031.

The past year brought Karius tests through Mayo Clinic Laboratories, Delve Bio's plasma test, Bruker's purchase of Noscendo's DISQVER platform, Oxford Nanopore's first diagnostic approval, the end of CDC's supplemental funding for national wastewater surveillance, states bringing wastewater testing in-house, new microbiome funding and the EQT offer for Qiagen. The report covers 23 chapters, 60 tables and 49 figures, with forecasts by application, technology, sample type, customer and product for 14 countries and regions, and profiles of 44 companies.

Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information.

Product Code: GENMETA 1026

Table of Contents

List of Tables

List of Figures

1. Executive Summary

  • 1.1 Situation Analysis
  • 1.2 Market Snapshot
  • 1.3 Key Findings
  • 1.4 Investment & Strategic Thesis

2. Research Methodology & Scope

  • 2.1 Scope & Market Definition
  • 2.2 Value Basis
  • 2.3 Market Segments
  • 2.4 Geographic Coverage
  • 2.5 Methodology
  • 2.6 Sources
  • 2.7 Author
  • 2.8 Limitations

3. Introduction to Metagenomic Sequencing

  • 3.1 What Metagenomics Is
  • 3.2 Three Ways to Sequence a Microbial Community
  • 3.3 Host Depletion, Reference Databases and Classification
  • 3.4 DNA, RNA and Metatranscriptomics
  • 3.5 A Short History
  • 3.6 The Industry and Its Players

4. The Global Market for Metagenomic Sequencing

  • 4.1 Global Market Overview by Country
  • 4.2 Global Market by Application - Overview
  • 4.3 Global Market by Technology - Overview
  • 4.4 Global Market by Sample Type - Overview
  • 4.5 Global Market by Customer - Overview
  • 4.6 Global Market by Product - Overview

5. Clinical Metagenomics for Infectious Disease

  • 5.1 The Diagnostic Problem
  • 5.2 Clinical Settings and Tests
  • 5.3 China's Clinical mNGS Market in Brief
  • 5.4 Clinical Evidence, Stewardship and Turnaround
  • 5.5 Reimbursement
  • 5.6 Competition with Culture and Syndromic PCR

6. Microbiome Research & Microbiome Products

  • 6.1 The Human Microbiome as a Research Field
  • 6.2 Gut, Vaginal and Skin Microbiomes
  • 6.3 Consumer and Practitioner Microbiome Tests
  • 6.4 Microbiome Therapeutics and Their Sequencing Demand
  • 6.5 Pharma, CRO and Service Use
  • 6.6 Outlook

7. Public Health, Wastewater & Biosurveillance

  • 7.1 From Emergency Tool to Permanent Infrastructure
  • 7.2 The US National Wastewater Surveillance System and Its Funding Cliff
  • 7.3 Targets: Measles, H5N1 and the Move to Pathogen-agnostic Testing
  • 7.4 International Programmes
  • 7.5 Airport, Travel and Biosecurity Surveillance
  • 7.6 Outlook for the Segment

8. Agriculture, Environment, Food & Industrial Applications

  • 8.1 Metagenomics Beyond the Clinic
  • 8.2 Soil and Crop Microbiome
  • 8.3 Livestock, Aquaculture and Animal Health
  • 8.4 Food Safety, Fermentation and Industrial Processes
  • 8.5 Environmental Monitoring and eDNA
  • 8.6 Outlook and Competitive Dynamics

9. Technology, Platforms & Bioinformatics

  • 9.1 How a Metagenomic Workflow is Built
  • 9.2 Sequencing Platforms
  • 9.3 Extraction, Library Preparation and Host Depletion
  • 9.4 Classification Software and Reference Databases
  • 9.5 Cost and Turnaround Comparison
  • 9.6 Technology Outlook

10. China & Asia-Pacific Metagenomics

  • 10.1 Regional Overview
  • 10.2 China's Clinical mNGS Market
  • 10.3 NMPA Approvals and Regulation in China
  • 10.4 Japan, South Korea, Taiwan, India, Australia and Singapore
  • 10.5 Outlook for Asia-Pacific

11. Regulation, Reimbursement & Funding

  • 11.1 Policy and the Metagenomics Market
  • 11.2 Regulation of Clinical Metagenomic Tests
  • 11.3 Reimbursement
  • 11.4 Public Funding for Surveillance and Research
  • 11.5 Data, Privacy and Ethics
  • 11.6 Outlook

12. Recent Developments

  • 12.1 CDC Wastewater Surveillance Faces a Funding Cliff
  • 12.2 Bruker Acquires Noscendo's DISQVER Blood Metagenomics Platform
  • 12.3 Delve Bio Launches Delve Detect Plasma and Publishes Stewardship Data
  • 12.4 Karius Tests Become Orderable Through Mayo Clinic Laboratories
  • 12.5 Massachusetts Ends Its Biobot Contract as States Bring Wastewater Testing In-House
  • 12.6 Oxford Nanopore Gains Its First Diagnostic Device Approval and Grows Clinical Revenue
  • 12.7 Microba Life Sciences Reports FY26 Results and Raises Capital
  • 12.8 Tiny Health Raises a $33 Million Series B
  • 12.9 Vedanta's Phase 3 VE303 Trial Continues After Interim Analysis
  • 12.10 CDC Studies Show Wastewater Detects Measles Early

13. Operations, Sample Handling & Supply Chain

  • 13.1 The Metagenomic Workflow
  • 13.2 Sample Collection, Transport and Extraction
  • 13.3 Contamination, Controls and Quality
  • 13.4 Laboratory Operations, Turnaround, Automation and Data
  • 13.5 Reagent Supply Chain and Service Laboratories
  • 13.6 Operational Outlook

14. Competitive Landscape

  • 14.1 Structure of Competition
  • 14.2 Tiers of Players
  • 14.3 Leading Players by Role
  • 14.4 Notable Acquisitions
  • 14.5 Competitive Dynamics
  • 14.6 Outlook for Competition

15. SWOT, Porter's Five Forces & Investment Risk Analysis

  • 15.1 SWOT Analysis
  • 15.2 Porter's Five Forces
  • 15.3 Investment Risk Analysis

16. Strategic Recommendations

  • 16.1 Guidance for Executives, Marketing, Sales and Business Development
  • 16.2 Guidance for Management Consultants and Investment Advisors

17. Market Forecast by Application, 2026-2031

  • 17.1 Clinical Infectious Disease
  • 17.2 Microbiome Research
  • 17.3 Agriculture & Environment
  • 17.4 Industrial & Other
  • 17.5 Public Health & Wastewater Surveillance

18. Market Forecast by Technology, 2026-2031

  • 18.1 16S / Amplicon
  • 18.2 Shotgun Metagenomics
  • 18.3 Long-read & Whole-Genome
  • 18.4 Other

19. Market Forecast by Sample Type, 2026-2031

  • 19.1 Human Gut & Stool
  • 19.2 Clinical Samples
  • 19.3 Environmental & Wastewater
  • 19.4 Agricultural
  • 19.5 Food & Industrial

20. Market Forecast by Customer, 2026-2031

  • 20.1 Academic
  • 20.2 Clinical Labs & Hospitals
  • 20.3 Pharma & Biotech
  • 20.4 Government & Other

21. Market Forecast by Product, 2026-2031

  • 21.1 Instruments
  • 21.2 Reagents & Kits
  • 21.3 Software & Bioinformatics
  • 21.4 Services

22. Company Profiles

  • 22.1 Agilent Technologies
  • 22.2 ARUP Laboratories
  • 22.3 BGI Genomics (PMseq)
  • 22.4 Biobot Analytics
  • 22.5 Biome Makers
  • 22.6 bioMerieux
  • 22.7 Bruker (including Noscendo DISQVER)
  • 22.8 Chan Zuckerberg Biohub (CZ ID)
  • 22.9 Cmbio (CosmosID, Clinical-Microbiomics)
  • 22.10 Delve Bio
  • 22.11 Element Biosciences
  • 22.12 Eurofins Scientific
  • 22.13 GT Molecular
  • 22.14 Hugobiotech
  • 22.15 Illumina
  • 22.16 Jumpcode Genomics
  • 22.17 Karius
  • 22.18 KingMed Diagnostics
  • 22.19 Macrogen
  • 22.20 Mayo Clinic Laboratories
  • 22.21 MGI Tech
  • 22.22 Microba Life Sciences
  • 22.23 Micronbrane Medical
  • 22.24 Miraterra (Trace Genomics)
  • 22.25 New England Biolabs
  • 22.26 Novogene
  • 22.27 One Codex
  • 22.28 Oxford Nanopore Technologies
  • 22.29 Pacific Biosciences
  • 22.30 Pathogenomix
  • 22.31 Pattern Ag
  • 22.32 Perimeter (formerly Ginkgo Biosecurity)
  • 22.33 Psomagen
  • 22.34 Qiagen
  • 22.35 Seres Therapeutics
  • 22.36 Sun Genomics
  • 22.37 Thermo Fisher Scientific
  • 22.38 Tiny Health
  • 22.39 Twist Bioscience
  • 22.40 Vedanta Biosciences
  • 22.41 Verily
  • 22.42 Viome
  • 22.43 Vision Medicals
  • 22.44 Zymo Research

23. Appendix

  • 23.1 Abbreviations
  • 23.2 Developments Archive
  • 23.3 Report Limitations Restated
Product Code: GENMETA 1026

List of Tables

  • Table 1 Key Market Indicators (constant 2026 US$)
  • Table 2 Global Market by Segment, 2026 and 2031 (US$ millions, constant 2026 dollars; segment values are rounded and may not add exactly to the total)
  • Table 3 Metagenomic Sequencing Approaches Compared
  • Table 4 Milestones in Metagenomic Sequencing
  • Table 5 Global Market by Country
  • Table 6 Global Market by Application
  • Table 7 Global Market by Technology
  • Table 8 Global Market by Sample Type
  • Table 9 Global Market by Customer
  • Table 10 Global Market by Product
  • Table 11 Clinical Metagenomics in the Market Segments
  • Table 12 Selected Clinical Metagenomic Tests
  • Table 13 Clinical Metagenomics Compared with Conventional Methods
  • Table 14 Microbiome Research in the Market Segments
  • Table 15 Selected Consumer and Practitioner Microbiome Test Companies
  • Table 16 Selected Microbiome Therapeutics
  • Table 17 Public Health and Wastewater-related Segment Lines, 2026 and 2031
  • Table 18 Wastewater and Biosurveillance Testing Approaches
  • Table 19 Agriculture, Environment, Food and Industrial Segment Lines, 2026 and 2031
  • Table 20 Agriculture, Environment, Food and Industrial Applications of Metagenomic Sequencing
  • Table 21 Metagenomic Sequencing Market by Technology, 2026 and 2031
  • Table 22 Indicative Cost and Turnaround of Metagenomic Approaches, 2026
  • Table 23 Asia-Pacific Metagenomic Sequencing Market by Country, 2026 and 2031
  • Table 24 Metagenomics in Selected Asia-Pacific Countries, October 2026
  • Table 25 Key Regulatory, Reimbursement and Funding Factors, October 2026
  • Table 26 Typical Metagenomic Workflows by Application
  • Table 27 Competitive Structure by Application
  • Table 28 Tiers of Metagenomic Sequencing Competitors
  • Table 29 Leading Sequencing Platforms for Metagenomics
  • Table 30 Leading Clinical Metagenomic Laboratories
  • Table 31 Leading Metagenomic Informatics Providers
  • Table 32 Notable Acquisitions in Metagenomic Sequencing
  • Table 33 SWOT Analysis - Strengths and Weaknesses
  • Table 34 SWOT Analysis - Opportunities and Threats
  • Table 35 Porter's Five Forces Ratings
  • Table 36 Investment Risk Matrix
  • Table 37 Selected Growth Opportunities
  • Table 38 Clinical Infectious Disease by Country
  • Table 39 Microbiome Research by Country
  • Table 40 Agriculture & Environment by Country
  • Table 41 Industrial & Other by Country
  • Table 42 Public Health & Wastewater Surveillance by Country
  • Table 43 16S / Amplicon by Country
  • Table 44 Shotgun Metagenomics by Country
  • Table 45 Long-read & Whole-Genome by Country
  • Table 46 Other by Country
  • Table 47 Human Gut & Stool by Country
  • Table 48 Clinical Samples by Country
  • Table 49 Environmental & Wastewater by Country
  • Table 50 Agricultural by Country
  • Table 51 Food & Industrial by Country
  • Table 52 Academic by Country
  • Table 53 Clinical Labs & Hospitals by Country
  • Table 54 Pharma & Biotech by Country
  • Table 55 Government & Other by Country
  • Table 56 Instruments by Country
  • Table 57 Reagents & Kits by Country
  • Table 58 Software & Bioinformatics by Country
  • Table 59 Services by Country
  • Table 60 Developments Archive: Items from the Previous Edition

List of Figures

  • Figure 1 Key Graphic - Infection and Surveillance Lead: Metagenomic Sequencing Market by Application, 2026 vs 2031
  • Figure 2 Global Market Pareto Chart
  • Figure 3 Global Market by Application - Base vs. Final
  • Figure 4 Global Market by Application Base Year
  • Figure 5 Global Market by Application End Year
  • Figure 6 Application Share by Year
  • Figure 7 Application Segments Growth
  • Figure 8 Global Market by Technology - Base vs. Final
  • Figure 9 Global Market by Technology Base Year
  • Figure 10 Global Market by Technology End Year
  • Figure 11 Technology Share by Year
  • Figure 12 Technology Segments Growth
  • Figure 13 Global Market by Sample Type - Base vs. Final
  • Figure 14 Global Market by Sample Type Base Year
  • Figure 15 Global Market by Sample Type End Year
  • Figure 16 Sample Type Share by Year
  • Figure 17 Sample Type Segments Growth
  • Figure 18 Global Market by Customer - Base vs. Final
  • Figure 19 Global Market by Customer Base Year
  • Figure 20 Global Market by Customer End Year
  • Figure 21 Customer Share by Year
  • Figure 22 Customer Segments Growth
  • Figure 23 Global Market by Product - Base vs. Final
  • Figure 24 Global Market by Product Base Year
  • Figure 25 Global Market by Product End Year
  • Figure 26 Product Share by Year
  • Figure 27 Product Segments Growth
  • Figure 28 Clinical Infectious Disease Growth
  • Figure 29 Microbiome Research Growth
  • Figure 30 Agriculture & Environment Growth
  • Figure 31 Industrial & Other Growth
  • Figure 32 Public Health & Wastewater Surveillance Growth
  • Figure 33 16S / Amplicon Growth
  • Figure 34 Shotgun Metagenomics Growth
  • Figure 35 Long-read & Whole-Genome Growth
  • Figure 36 Other Growth
  • Figure 37 Human Gut & Stool Growth
  • Figure 38 Clinical Samples Growth
  • Figure 39 Environmental & Wastewater Growth
  • Figure 40 Agricultural Growth
  • Figure 41 Food & Industrial Growth
  • Figure 42 Academic Growth
  • Figure 43 Clinical Labs & Hospitals Growth
  • Figure 44 Pharma & Biotech Growth
  • Figure 45 Government & Other Growth
  • Figure 46 Instruments Growth
  • Figure 47 Reagents & Kits Growth
  • Figure 48 Software & Bioinformatics Growth
  • Figure 49 Services Growth
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!